Nontuberculous Mycobacterial Infection Market Report 2026

Nontuberculous Mycobacterial Infection Market Overview

• Nontuberculous Mycobacterial Infection market size has reached to $14.96 billion in 2025 • Expected to grow to $21.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market • Market Trend: Innovations In Boron-Based Antibiotics Enhance Treatment Efficacy And Address Drug-Resistant Nontuberculous Mycobacterial Infections • North America was the largest region and fastest growing region.

What Is Covered Under Nontuberculous Mycobacterial Infection Market?

A nontuberculous mycobacterial (NTM) infection is an infectious disease caused by various species of mycobacteria other than mycobacterium tuberculosis, which is responsible for tuberculosis (TB). The role of nontuberculous mycobacterial (NTM) infections is primarily related to their impact on human health and their interaction with the immune system. The main classes of drugs for nontuberculous mycobacterial infection are macrolides, rifampin, aminoglycoside and others. Macrolides are a class of antibiotics that are commonly used to treat a variety of bacterial infections. They can be administered through oral, parenteral and other routes, which can be distributed by various channels such as hospital pharmacies, retail pharmacies and online pharmacies.

What Is The Nontuberculous Mycobacterial Infection Market Growth Forecast?

The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few years. It will grow to $21.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising adoption of macrolide and rifampin combination therapies, increasing availability of aminoglycosides, growth of personalized treatment approaches, expansion of hospital and specialty pharmacy networks, development of ai-enabled monitoring and diagnostic tools. Major trends in the forecast period include rising adoption of macrolide and rifampin therapies, increasing use of aminoglycoside-based treatments, growing implementation of combination drug regimens, expanding deployment of advanced diagnostic tools, advancing integration of ai-powered treatment monitoring.

Global Nontuberculous Mycobacterial Infection Market Segmentation

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes 2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin 2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy 3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin 4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine

What Is The Driver Of The Nontuberculous Mycobacterial Infection Market?

The rising prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the nontuberculous mycobacterial infection market going forward. Chronic obstructive pulmonary disease (COPD) is a chronic respiratory condition characterized by persistent and often progressive lung airflow limitation. Nontuberculous mycobacterial (NTM) infections in patients with COPD are associated with a more significant decline in forced expiratory volume in one second (FEV1) and an increased exacerbation rate. COPD may weaken the immune system and damage the lung tissue, making it easier for NTM bacteria to infect the lungs. For instance, in September 2024, according to Public Health Scotland, a Scotland-based government health agency, in Scotland during 2022/23, the incidence of COPD, based on hospital admissions and death records, was 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Therefore, the rising prevalence of chronic obstructive pulmonary disease (COPD) drives the growth of the nontuberculous mycobacterial infection industry.

Key Players In The Global Nontuberculous Mycobacterial Infection Market

Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.

Global Nontuberculous Mycobacterial Infection Market Trends and Insights

Major companies operating in the nontuberculous mycobacterial infection market are focusing on developing advanced solutions, such as boron-based antibiotics, to enhance treatment efficacy, overcome drug resistance, and improve patient outcomes. Boron-based antibiotics are small-molecule therapies designed to inhibit bacterial protein synthesis, offering potent and safer options for persistent infections. For instance, in September 2023, AN2 Therapeutics, a US-based biopharmaceutical company, initiated enrolment in the Phase 3 part of its pivotal Phase 2/3 clinical trial for epetraborole in treatment-refractory Mycobacterium avium complex lung disease after completing Phase 2 enrolments. Designed for oral administration, epetraborole demonstrated potential in preclinical studies to treat Mycobacterium abscessus infections, aiming to reduce treatment duration, improve tolerability, and address unmet medical needs in rare and serious infectious lung diseases, thereby supporting enhanced patient outcomes and disease management.

What Are Latest Mergers And Acquisitions In The Nontuberculous Mycobacterial Infection Market?

In February 2023, Qurient Co. Ltd., a Korea-based biotech company, partnered with TB Alliance. This partnership aims to develop telacebec, a drug to treat tuberculosis and other nontuberculous mycobacteria (NTM) infections. TB Alliance will be granted the only global license for Telacebec through the agreement. This indicates that the TB Alliance will have the authority to continue working on the medicine and market it internationally. TB Alliance is a South Africa-based non-profit organization that develops and delivers economic TB medications.

Regional Outlook

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nontuberculous Mycobacterial Infection Market?

The nontuberculous mycobacterial infection market consists of revenues earned by entities by providing services such as treatment planning, antibiotic therapy, monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The nontuberculous mycobacterial infection market also includes sales of azithromycin, rifampin, ethambutol, streptomycin, medical equipment, pulmonary rehabilitation and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nontuberculous Mycobacterial Infection Market Report 2026?

The nontuberculous mycobacterial infection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nontuberculous mycobacterial infection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.